+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease



Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease



Brain 126(Pt 1): 32-42



To date, two point mutations, G209A and G88C, have been reported in the coding region of the alpha-synuclein gene in autosomal dominant familial Parkinson's disease. When translated, these lead to the missense mutations Ala53Thr and Ala30Pro, respectively. Reduced mRNA expression of the G209A allele was reported recently in a Greek-American family. Here, we show that alpha-synuclein mRNA is normally expressed in blood cells and report the results of an analysis of alpha-synuclein mRNA and protein expression in lymphoblastoid cell lines established from kindreds with the G209A and G88C mutations. mRNA expression was characterized using a TaqMan real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) assay. We assessed five affected and three unaffected members of a German family with the G88C mutation and two affected members in different, unrelated Greek families with the G209A mutation. The ratio of wild-type to mutant alpha-synuclein allele expression ranged from 2.2 to 9.2 in the affected individuals with a severe clinical phenotype. The ratios of the expression levels of the wild-type to mutant alleles were only slightly decreased in mild cases and were less than 1.0 in two asymptomatic heterozygotes. Sequence analysis of the RT-PCR products showed only the presence of G in position 88 and G in position 209 in severely affected heterozygotes of the German and Greek families, respectively. High performance liquid chromatography/mass spectrometry demonstrated that, relative to wild-type alpha-synuclein, there is a reduction of Ala30Pro alpha-synuclein in lymphoblastoid cell lines originating from severely affected, but not mildly affected G88C/+ heterozygotes. Taken together, these data indicate that there is haploinsufficiency at the alpha-synuclein gene and that the ratio of expression of the wild-type to mutant alleles correlates with the severity of the clinical phenotype. Furthermore, these findings suggest that haploinsufficiency of alpha-synuclein mutations may contribute to disease progression in these forms of familial Parkinson's disease.

(PDF emailed within 1 workday: $29.90)

Accession: 046211956

Download citation: RISBibTeXText

PMID: 12477695


Related references

Haploinsufficiency at the -synuclein gene underlies phenotypic severity in familial Parkinson's disease. Brain 126(1): 32-42, 2003

Sequencing of the alpha-synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD). Human Molecular Genetics 7(4): 751-753, 1998

Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 99(13): 8968-8973, 2002

Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 fwdarw Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 99(13): 8968-8973, June 25, 2002

Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364(9440): 1169-1171, 2004

The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics 2(3): 191-192, 1999

Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Experimental Neurology 187(2): 279-288, 2004

Failure to find alpha-synuclein gene dosage changes in 190 patients with familial Parkinson disease. Archives of Neurology 62(1): 96-98, 2005

Study on exons 3 and 4 of alpha-synuclein gene in Chinese familial Parkinson disease patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 20(6): 536-538, 2003

Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease. Mechanisms of Ageing and Development 128(5-6): 378-382, 2007

Lack of mutation G209A in the alpha-synuclein gene in French patients with familial and sporadic Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 65(6): 948-949, 1998

The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Archives of Neurology 55(12): 1521-1523, 1998

GBA haploinsufficiency accelerates alpha synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson's disease=. Human Molecular Genetics 2019, 2019

Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the alpha-synuclein gene in early onset patients. Neuroscience Letters 235(1-2): 57-60, 1997

Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. European Journal of Neurology 10(3): 281-286, 2003